Inflammatory bowel disease in women of reproductive age

Expert Review of Gastroenterology and Hepatology

Volumn 8, Issue 4, 2014, Pages 417-425

  De Felice, Kara M ^a   Kane, Sunanda V ^a  

^a MAYO CLINIC   (United States)

Author keywords

aminosalicylates; antibiotics; biologic; breastfeeding; Crohns disease; fertility; immunomodulators; inflammatory bowel disease; pregnancy; ulcerative colitis

Indexed keywords

ADALIMUMAB; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZATHIOPRINE; BALSALAZIDE; BUDESONIDE; CERTOLIZUMAB PEGOL; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN; FOLIC ACID; GOLIMUMAB; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; NATALIZUMAB; OLSALAZINE; PROBIOTIC AGENT; RIFAXIMIN; SALAZOSULFAPYRIDINE; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ABDOMINAL ABSCESS; ANUS FISTULA; BREAST FEEDING; CESAREAN SECTION; CLOSTRIDIUM DIFFICILE INFECTION; CROHN DISEASE; DIARRHEA; DRUG MILK LEVEL; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FEMALE FERTILITY; FETUS OUTCOME; HERITABILITY; HUMAN; ILEITIS; ILEOANAL ANASTOMOSIS; INFLAMMATORY BOWEL DISEASE; MALE INFERTILITY; MEDICATION COMPLIANCE; MULTIPLE SCLEROSIS; OLIGOSPERMIA; PATIENT EDUCATION; PLACENTAL TRANSFER; PREGNANCY OUTCOME; PRENATAL DRUG EXPOSURE; REMISSION; REVIEW; TERATOGENICITY; ULCERATIVE COLITIS; ADULT; FERTILITY; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; PREGNANCY; PREGNANCY COMPLICATION;

ADULT; BREAST FEEDING; FEMALE; FERTILITY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 84899000253     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2014.893822     Document Type: Review

References (92)

1. Laharie D, Debeugny S, Peeters M, et al. Inflammatory bowel disease in spouses and their offspring. Gastroenterology 2001;120: 816-19 (Pubitemid 32193177)
2. Malmborg P, Bahmanyar S, Grahnquist L, et al. Cesarean section and the risk of pediatric Crohn's disease. Inflamm Bowel Dis 2012;18:703-8
3. Bager P, Simonsen J, Nielsen NM, Frisch M. Cesarean section and offspring's risk of inflammatory bowel disease: a national cohort study. Inflamm Bowel Dis 2012;18:857-62
4. Mountifield R, Bampton P, Prosser R, et al. Fear and fertility in inflammatory bowel disease: a mismatch of perception and reality affects family planning decisions. Inflamm Bowel Dis 2009;15:720-5
5. Ording Olsen K, Juul S, Berndtsson I, et al. Ulcerative colitis: female fecundity before diagnosis, during disease, and after surgery compared with a population sample. Gastroenterology 2002;122:15-19 (Pubitemid 34049189)
6. Olsen KO, Joelsson M, Laurberg S, Oresland T. Fertility after ileal pouch-anal anastomosis in women with ulcerative colitis. Br J Surg 1999;86:493-5 (Pubitemid 29195043)
7. Bartels SA, D'Hoore A, Cuesta MA, et al. Significantly increased pregnancy rates after laparoscopic restorative proctocolectomy: a cross-sectional study. Ann Surg 2012;256: 1045-8
8. O'Morain C, Smethurst P, Dore CJ, Levi AJ. Reversible male infertility due to sulphasalazine: studies in man and rat. Gut 1984;25:1078-84 (Pubitemid 14002122)
9. French AE, Koren G. Effect of methotrexate on male fertility. Can Fam Physician 2003;49:577-8
10. Villiger PM, Caliezi G, Cottin V, et al. Effects of TNF antagonists on sperm characteristics in patients with spondyloarthritis. Ann Rheum Dis 2010;69: 1842-4
11. Tiainen J, Matikainen M, Hiltunen KM. Ileal J-pouch - anal anastomosis, sexual dysfunction, and fertility. Scand J Gastroenterol 1999;34:185-8 (Pubitemid 29138870)
12. Cornish J, Tan E, Teare J, et al. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut 2007;56:830-7 (Pubitemid 46854200)
13. Baiocco PJ, Korelitz BI. The influence of inflammatory bowel disease and its treatment on pregnancy and fetal outcome. J Clin Gastroenterol 1984;6: 211-16 (Pubitemid 14116669)
14. Bortoli A, Pedersen N, Duricova D, et al. Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003-2006. Aliment Pharmacol Ther 2011;34:724-34
15. Mahadevan U, Sandborn WJ, Li DK, et al. Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology 2007;133: 1106-12 (Pubitemid 47494456)
16. Stephansson O, Larsson H, Pedersen L, et al. Congenital abnormalities and other birth outcomes in children born to women with ulcerative colitis in Denmark and Sweden. Inflamm Bowel Dis 2011;17: 795-801
17. Stephansson O, Larsson H, Pedersen L, et al. Crohn's disease is a risk factor for preterm birth. Clin Gastroenterol Hepatol 2010;8:509-15
18. Molna'r T, Farkas K, Nagy F, et al. Pregnancy outcome in patients with inflammatory bowel disease according to the activity of the disease and the medical treatment: a case-control study. Scand J Gastroenterol 2010;45:1302-6
19. Pedersen N, Bortoli A, Duricova D, et al. The course of inflammatory bowel disease during pregnancy and postpartum: a prospective European ECCO-EpiCom Study of 209 pregnant women. Aliment Pharmacol Ther 2013;38:501-12
20. Kane S, Lemieux N. The role of breastfeeding in postpartum disease activity in women with inflammatory bowel disease. Am J Gastroenterol 2005;100:102-5 (Pubitemid 41623276)
21. Mogadam M, Korelitz BI, Ahmed SW, et al. The course of inflammatory bowel disease during pregnancy and postpartum. Am J Gastroenterol 1981;75:265-9 (Pubitemid 11086914)
22. De Santis M, Straface G, Cavaliere AF, et al. Gadolinium periconceptional exposure: pregnancy and neonatal outcome. Acta Obstet Gynecol Scand 2007;86:99-101 (Pubitemid 46009534)
23. Cappell MS, Colon VJ, Sidhom O. A. A study at 10 medical centers of the safety and efficacy of 48 flexible sigmoidoscopies and 8 colonoscopies during pregnancy with follow-up of fetal outcome and with comparison to control groups. Dig Dis Sci 1996;41:2353-61
24. Ilnyckyji A, Blanchard JF, Rawsthorne P, Bernstein CN. Perianal Crohn's disease and pregnancy: role of the mode of delivery. Am J Gastroenterol 1999;94:3274-8
25. Ravid A, Richard CS, Spencer LM, et al. Pregnancy, delivery, and pouch function after ileal pouch-anal anastomosis for ulcerative colitis. Dis Colon Rectum 2002;45:1283-8 (Pubitemid 35176036)
26. Moffatt DC, Ilnyckyj A, Bernstein CN. A population-based study of breastfeeding in inflammatory bowel disease: initiation, duration, and effect on disease in the postpartum period. Am J Gastroenterol 2009;104:2517-23
27. Flechner SM, Katz AR, Rogers AJ, et al. The presence of cyclosporine in body tissues and fluids during pregnancy. Am J Kidney Dis 1985;5:60-3 (Pubitemid 15125986)
28. Johns DG, Rutherford LD, Leighton PC, Vogel CL. Secretion of methotrexate into human milk. Am J Obstet Gynecol 1972;112:978-80
29. Julsgaard M, Norgaard M, Hvas CL, et al. Self-reported adherence to medical treatment prior to and during pregnancy among women with ulcerative colitis. Inflamm Bowel Dis 2011;17:1573-80
30. Holubar SD, Cima RR, Sandborn WJ, Pardi DS. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev 2010(6):CD001176
31. Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995;108: 1617-21
32. Koss CA, Baras DC, Lane SD, et al. Investigation of metronidazole use during pregnancy and adverse birth outcomes. Antimicrob Agents Chemother 2012;56: 4800-5
33. Loebstein R, Addis A, Ho E, et al. Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study. Antimicrob Agents Chemother 1998;42:1336-9 (Pubitemid 28257627)
34. Bar-Oz B, Moretti ME, Boskovic R, et al. The safety of quinolones - a meta-analysis of pregnancy outcomes. Eur J Obstet Gynecol Reprod Biol 2009;143:75-8
35. Isaacs KL, Sandler RS, Abreu M, et al. Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis 2007;13:1250-5 (Pubitemid 47597772)
36. Prantera C, Lochs H, Grimaldi M, Retic Study Group (Rifaximin-Eir Treatment in Crohn's Disease). Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease. Gastroenterology 2012;142:473-81. e474
37. Allen SJ, Jordan S, Storey M, et al. Dietary supplementation with lactobacilli and bifidobacteria is well tolerated and not associated with adverse events during late pregnancy and early infancy. J Nutr 2010;140:483-8
38. Dugoua JJ, Machado M, Zhu X, et al. Probiotic safety in pregnancy: a systematic review and meta-analysis of randomized controlled trials of Lactobacillus, Bifidobacterium, and Saccharomyces spp. J Obstet Gynaecol Can 2009;31:542-52
39. Huurre A, Laitinen K, Rautava S, et al. Impact of maternal atopy and probiotic supplementation during pregnancy on infant sensitization: a double-blind placebocontrolled study. Clin Exp Allergy 2008;38: 1342-8 (Pubitemid 352019662)
40. Kukkonen K, Savilahti E, Haahtela T, et al. Long-term safety and impact on infection rates of postnatal probiotic and prebiotic (synbiotic) treatment: randomized, double-blind, placebo-controlled trial. Pediatrics 2008;122:8-12
41. Abrahamsson TR, Sinkiewicz G, Jakobsson T, et al. Probiotic lactobacilli in breast milk and infant stool in relation to oral intake during the first year of life. J Pediatr Gastroenterol Nutr 2009;49:349-54
42. Diav-Citrin O, Park YH, Veerasuntharam G, et al. The safety of mesalamine in human pregnancy: a prospective controlled cohort study. Gastroenterology 1998;114:23-8 (Pubitemid 28020950)
43. Hernandez-Diaz S, Mitchell AA, Kelley KE, et al. Medications as a potential source of exposure to phthalates in the U.S. population. Environ Health Perspect 2009;117:185-9
44. Baggott JE, Morgan SL, Ha T, et al. Inhibition of folate-dependent enzymes by non-steroidal anti-inflammatory drugs. Biochem J 1992;282(Pt 1):197-202
45. Mahadevan U, Kane S. American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology 2006;131:283-311 (Pubitemid 44015759)
46. Rahimi R, Nikfar S, Rezaie A, Abdollahi M . Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis. Reprod Toxicol 2008;25: 271-5
47. Klotz U, Harings-Kaim A. Negligible excretion of 5-aminosalicylic acid in breast milk. Lancet 1993;342:618-19 (Pubitemid 23259249)
48. Carmichael SL, Shaw GM. Maternal corticosteroid use and risk of selected congenital anomalies. Am J Med Genet 1999;86:242-4 (Pubitemid 29465870)
49. Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000;62:385-92
50. Gur C, Diav-Citrin O, Shechtman S, et al. Pregnancy outcome after first trimester exposure to corticosteroids: a prospective controlled study. Reprod Toxicol 2004;18: 93-101 (Pubitemid 38175451)
51. Hviid A, Molgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ 2011;183: 796-804
52. Ostensen M, Forger F. Management of RA medications in pregnant patients. Nat Rev Rheumatol 2009;5:382-90
53. Tegethoff M, Pryce C, Meinlschmidt G. Effects of intrauterine exposure to synthetic glucocorticoids on fetal, newborn, and infant hypothalamic-pituitary- adrenal axis function in humans: a systematic review. Endocr Rev 2009;30:753-89
54. Norgard BM. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy. Dan Med Bull 2011;58:B4360
55. Beaulieu DB, Ananthakrishnan AN, Issa M, et al. Budesonide induction and maintenance therapy for Crohn's disease during pregnancy. Inflamm Bowel Dis 2009;15:25-8
56. Beitins IZ, Bayard F, Ances IG, et al. The transplacental passage of prednisone and prednisolone in pregnancy near term. J Pediatr 1972;81:936-45
57. Matalon ST, Ornoy A, Lishner M. Review of the potential effects of three commonly used antineoplastic and immunosuppressive drugs (cyclophosphamide, azathioprine, doxorubicin on the embryo and placenta). Reprod Toxicol 2004;18:219-30 (Pubitemid 38333046)
58. Polifka JE, Friedman JM. Teratogen update: azathioprine and 6-mercaptopurine. Teratology 2002;65:240-61 (Pubitemid 34492613)
59. Cleary BJ, Kallen B. Early pregnancy azathioprine use and pregnancy outcomes. Birth Defects Res A Clin Mol Teratol 2009;85:647-54
60. Norgard B, Pedersen L, Fonager K, et al. Azathioprine, mercaptopurine and birth outcome: a population-based cohort study. Aliment Pharmacol Ther 2003;17:827-34 (Pubitemid 36418880)
61. Akbari M, Shah S, Velayos FS, et al. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis 2013;19:15-22
62. Hutson JR, Matlow JN, Moretti ME, Koren G. The fetal safety of thiopurines for the treatment of inflammatory bowel disease in pregnancy. J Obstet Gynaecol 2013;33: 1-8
63. Coelho J, Beaugerie L, Colombel JF, et al. Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. Gut 2011;60:198-203
64. Casanova MJ, Chaparro M, Domenech E, et al. Safety of thiopurines and anti- TNF-alpha drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol 2013;108:433-40
65. Mahadevan U, Martin CF, Sandler RS, et al. 865 PIANO: A 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy. Gastroenterology 2012;142:S-149
66. Langagergaard V, Pedersen L, Gislum M, et al. Birth outcome in women treated with azathioprine or mercaptopurine during pregnancy: a Danish nationwide cohort study. Aliment Pharmacol Ther 2007;25: 73-81 (Pubitemid 44902866)
67. Teruel C, Lo'pez-San Roma'n A, Bermejo F, et al. Outcomes of pregnancies fathered by inflammatory bowel disease patients exposed to thiopurines. Am J Gastroenterol 2010;105:2003-8
68. Hoeltzenbein M, Weber-Schoendorfer C, Borisch C, et al. Pregnancy outcome after paternal exposure to azathioprine/ 6-mercaptopurine. Reprod Toxicol 2012;34: 364-9
69. Christensen LA, Dahlerup JF, Nielsen MJ, et al. Azathioprine treatment during lactation. Aliment Pharmacol Ther 2008;28: 1209-13
70. Angelberger S, Reinisch W, Messerschmidt A, et al. Long-term follow-up of babies exposed to azathioprine in utero and via breastfeeding. J Crohns Colitis 2011;5:95-100
71. Lloyd ME, Carr M, McElhatton P, et al. The effects of methotrexate on pregnancy, fertility and lactation. QJM 1999;92:551-63 (Pubitemid 29501961)
72. Martinez Lopez JA, Loza E, Carmona L. Systematic review on the safety of methotrexate in rheumatoid arthritis regarding the reproductive system (fertility, pregnancy, and breastfeeding). Clin Exp Rheumatol 2009;27:678-84
73. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-5 (Pubitemid 24188135)
74. Bar Oz B, Hackman R, Einarson T, Koren G. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation 2001;71: 1051-5 (Pubitemid 32448816)
75. Branche J, Cortot A, Bourreille A, et al. Cyclosporine treatment of steroid-refractory ulcerative colitis during pregnancy. Inflamm Bowel Dis 2009;15:1044-8
76. Sandborn WJ, Present DH, Isaacs KL, et al. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology 2003;125:380-8 (Pubitemid 36929418)
77. Zheng S, Easterling TR, Umans JG, et al. Pharmacokinetics of tacrolimus during pregnancy. Ther Drug Monit 2012;34: 660-70
78. Kainz A, Harabacz I, Cowlrick IS, et al. Analysis of 100 pregnancy outcomes in women treated systemically with tacrolimus. Transpl Int 2000;13(Suppl 1):S299-300
79. Jain AB, Reyes J, Marcos A, et al. Pregnancy after liver transplantation with tacrolimus immunosuppression: a single center's experience update at 13 years. Transplantation 2003;76:827-32 (Pubitemid 37140228)
80. Baumgart DC, Sturm A, Wiedenmann B, Dignass AU. Uneventful pregnancy and neonatal outcome with tacrolimus in refractory ulcerative colitis. Gut 2005;54: 1822-3 (Pubitemid 41697694)
81. French AE, Soldin SJ, Soldin OP, Koren G. Milk transfer and neonatal safety of tacrolimus. Ann Pharmacother 2003;37: 815-18 (Pubitemid 36618367)
82. Kane S. Anti-tumor necrosis factor agents and placental transfer: relevant clinical data for rational decision-making. Clin Gastroenterol Hepatol 2013;11:293-4
83. Arsenescu R, Arsenescu V, de Villiers WJ. TNF-alpha and the development of the neonatal immune system: implications for inhibitor use in pregnancy. Am J Gastroenterol 2011;106:559-62
84. Martin PL, Oneda S, Treacy G. Effects of an anti-TNF-alpha monoclonal antibody, administered throughout pregnancy and lactation, on the development of the macaque immune system. Am J Reprod Immunol 2007;58:138-49 (Pubitemid 47097380)
85. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol 2012;107:1409-22
86. Ju?rgens M, Brand S, Filik L, et al. Safety of adalimumab in Crohn's disease during pregnancy: case report and review of the literature. Inflamm Bowel Dis 2010;16: 1634-6
87. Cheent K, Nolan J, Shariq S, et al. Case Report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. J Crohns Colitis 2010;4:603-5
88. Zelinkova Z, van der Ent C, Bruin KF, Dutch Delta IBD Group. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure. Clin Gastroenterol Hepatol 2013;11:318-21
89. Ben-Horin S, Yavzori M, Katz L, et al. Adalimumab level in breast milk of a nursing mother. Clin Gastroenterol Hepatol 2010;8:475-6
90. Ben-Horin S, Yavzori M, Kopylov U, et al. Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. J Crohns Colitis 2011;5:555-8
91. Wakefield I, Stephens S, Foulkes R, et al. The use of surrogate antibodies to evaluate the developmental and reproductive toxicity potential of an anti-TNFalpha PEGylated Fab' monoclonal antibody. Toxicol Sci 2011;122:170-6
92. Hellwig K, Haghikia A, Gold R. Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment. Mult Scler 2011;17: 958-63